<DOC>
	<DOCNO>NCT02372942</DOCNO>
	<brief_summary>Primary endpoint evaluate effectiveness vaginal lactoferrin reduction 30 % preterm delivery versus use progesterone , specific select patient , consequent improvement neonatal outcome . Secondary endpoint compare antibacterial anti-inflammatory activity lactoferrin evaluation systemic biochemical urinary marker .</brief_summary>
	<brief_title>Lactoferrin Progesterone Prevention Preterm Delivery</brief_title>
	<detailed_description>AIM OF THE STUDY Primary endpoint evaluate effectiveness vaginal lactoferrin reduction 30 % preterm delivery versus use progesterone , specific select patient , consequent improvement neonatal outcome . Secondary endpoint compare antibacterial anti-inflammatory activity lactoferrin evaluation systemic biochemical urinary marker . MATHERIAL AND METHODS Type study : This randomize open-label study ( lactoferrin v progesterone ) , multicenter . Population study : pregnant woman 18-43 year age singleton pregnancy , 24 34 week ' gestation , risk preterm delivery . Investigational product : - Lactoferrin ( Difesan , vaginal tablet 300 mg ) ; use acute vaginosis ( 300 mg intravaginally day seven consecutives day ) . Since side effect , experimental purpose use 34 week gestation . - Progesterone ( Progeffik , vaginal suppository 200 mg ) ; case risk premature delivery treatment consist 200 mg intravaginally day , maximum 10 week . In protocol use 34 week gestation . Duration study : consider prevalence disease number delivery year , conclude 2015 . Centers : Department Women 's Child 's Health , Obstetrics Gynecology Clinic , University Padua , Italy . Others : Udine , Italy `` S. Maria della Misericordia Hospital '' Vicenza , Italy `` S. Bortolo Hospital '' Ferrara , Italy Bologna , Italy Treviso , Italy Inclusion criterion : - cervical length le 25 mm 24 34 week ' gestation ( without funnel ) - cervical effacement le 50 percent cervical dilatation le 3 cm - uterine contraction le 4 30 minute - singleton pregnancy - absence chorioamnionitis sign ( white cell count &lt; 15.000 , Reactive Protein C &lt; 10 mg/l , Procalcitonin level &lt; 0,05 ng/ml ) , - absence premature membrane rupture ( pPROM ) . Exclusion criterion : 1 . Fetal abnormality severe intrauterine growth restriction fetal malformation progressive deterioration 2 . Maternal disease gestation diabetes insulin-treated , severe nephropaties , severe cardiopathy , autoimmune diseases 3 . Twin pregnancy 4 . Signs maternal infection ( chorioamnionitis ) 5 . Premature rupture membrane Previous progesterone therapy first trim contraindication inclusion patient ( interval least 8-10 week gestation ) . Previous preterm birth exclusion criterion randomization . Evaluation scheme : 1 . Verification maternal compatibility study criterion . 2 . Accurate personal , familiar obstetrical anamnesis . 3 . Management patient accord clinical protocol case risk premature delivery ( induction fetal lung maturity tocolitic therapy ) 4 . Informed consent . 5 . Patient randomization . 6 . Obstetrical ultrasound evaluation pregnancy ( cervical length , fetal growth fetal well-being 7 , 15 30 day randomize ) . 7 . Monitoring inflammatory marker ( white blood cell , reactive protein C procalcitonin ) diagnosis , 7 15 day recovery . 8 . Execution vaginal swab urine culture diagnosis 30 day recovery . 9 . Registration pregnancy data , delivery neonatal come . EXCLUSION CRITERIA The patient exclude study occur follow condition administration lactoferrin progesterone : 1 . Presence regular , painful frequent uterine contraction progressive change cervix ( cervical effacement 80 percent great cervical dilatation great 3 cm ) 2 . Modification inflammatory marker associate change obstetrical visit cervical length . There cost check-up expect patient belong clinic routine . The patient pay treatment provide Principal Investigator . MEASUREMENT 1 . Obstetrical data : recovery till delivery ( course pregnancy , sonography examination , biochemical test , complication . 2 . Perinatal data : gestational age time delivery , way delivery , sex , weight , Apgar score , arterial venous ph , base excess , p02 , day recovery neonatal intensive care unit , mechanical ventilation , neonatal morbidity , breastfeed . 3 . Epidemiological data : maternal paternal data ( age , BMI , smoke socio-economical status , parity , ethnic group , personal history ) . Familiar history . SAMPLE SIZE The patient enrol study treat high risk preterm delivery respect inclusion criterion . They randomize two group , one group submit lactofferin , group receive progesterone . For calculation sample size consider recent review conclude progesterone treatment decrease median risk preterm birth 22 % ( Likis F et al . Progestogens preterm birth prevention . Obstet Gynecol October 2012 ) . The primary outcome show lactoferrin decrease median risk preterm birth 30 % ; We consider alfa 5 % predictive value 80 % ; consider 10 % drop randomize 1030 woman . [ n=p1 ( p1-100 ) +p2 ( p2-100 ) / ( p1-p2 ) 2 x 7.9 ]</detailed_description>
	<mesh_term>Premature Birth</mesh_term>
	<mesh_term>Progesterone</mesh_term>
	<mesh_term>Lactoferrin</mesh_term>
	<criteria>Cervical length le 25 mm 24 34 week ' gestation ( without funnel ) cervical effacement le 50 percent cervical dilatation le 3 cm uterine contraction le 4 30 minute singleton pregnancy absence chorioamnionitis sign ( white cell count &lt; 15.000 , Reactive Protein C &lt; 10 mg/l , Procalcitonin level &lt; 0,05 ng/ml ) , absence premature membrane rupture ( pPROM ) . Fetal abnormality severe intrauterine growth restriction fetal malformation progressive deterioration Maternal diseases gestation diabetes insulintreated , severe nephropaties , severe cardiopathy , autoimmune disease Twin pregnancy Signs maternal infection ( chorioamnionitis ) Premature rupture membrane</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>43 Years</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>efficacy</keyword>
	<keyword>prevention</keyword>
</DOC>